References of "Tabarin, A"
     in
Bookmark and Share    
Full Text
Peer Reviewed
See detailCabergoline for Cushing's disease: a large retrospective multicenter study.
Ferriere, A.; Cortet, C.; Chanson, P. et al

in European Journal of Endocrinology (2017), 176(3), 305-314

OBJECTIVE: The efficacy of cabergoline in Cushing's disease (CD) is controversial. The aim of this study was to assess the efficacy and tolerability of cabergoline in a large contemporary cohort of ... [more ▼]

OBJECTIVE: The efficacy of cabergoline in Cushing's disease (CD) is controversial. The aim of this study was to assess the efficacy and tolerability of cabergoline in a large contemporary cohort of patients with CD. DESIGN: We conducted a retrospective multicenter study from thirteen French and Belgian university hospitals. METHODS: Sixty-two patients with CD received cabergoline monotherapy or add-on therapy. Symptom score, biological markers of hypercortisolism and adverse effects were recorded. RESULTS: Twenty-one (40%) of 53 patients who received cabergoline monotherapy had normal urinary free cortisol (UFC) values within 12 months (complete responders), and five of these patients developed corticotropic insufficiency. The fall in UFC was associated with significant reductions in midnight cortisol and plasma ACTH, and with clinical improvement. Compared to other patients, complete responders had similar median baseline UFC (2.0 vs 2.5xULN) and plasma prolactin concentrations but received lower doses of cabergoline (1.5 vs 3.5 mg/week, P < 0.05). During long-term treatment (>12 months), cabergoline was withdrawn in 28% of complete responders because of treatment escape or intolerance. Overall, sustained control of hypercortisolism was obtained in 23% of patients for 32.5 months (19-105). Nine patients on steroidogenesis inhibitors received cabergoline add-on therapy for 19 months (1-240). Hypercortisolism was controlled in 56% of these patients during the first year of treatment with cabergoline at 1.0 mg/week (0.5-3.5). CONCLUSIONS: About 20-25% of CD patients are good responders to cabergoline therapy allowing long-term control of hypercortisolism at relatively low dosages and with acceptable tolerability. No single parameter, including the baseline UFC and prolactin levels, predicted the response to cabergoline. [less ▲]

Detailed reference viewed: 31 (3 ULg)
Full Text
See detailUtilisation de la cabergoline dans le traitement palliatif de la maladie de Cushing : l'étude Frenchcab
Ferriere, A; Cortet, C; Chanson, P et al

in Annales d'Endocrinologie : 33ème congrès de la Société Française d'Endocrinologie (2016, October)

Detailed reference viewed: 30 (1 ULg)
Full Text
See detailClinical and genetic studies in patients with Pituitary/Parathyroid variant of MEN1 without MEN1 gene mutation : the French GENEM collaborative study
VALDES SOCIN, Hernan Gonzalo ULg; Burlacu, C; Delemer, B et al

in Abstract Book - 13th International Workshop on Multiple Endocrine Neoplasia (2012, September)

Detailed reference viewed: 27 (4 ULg)
Full Text
Peer Reviewed
See detailClinical characterization of cabergoline resistant prolactinomas : a multicenter experience on 92 patients
VROONEN, Laurent ULg; Jaffrain Rea, ML; PETROSSIANS, Patrick ULg et al

in Annales d'Endocrinologie (2012, April), 73(2), 153

Detailed reference viewed: 43 (5 ULg)
Full Text
Peer Reviewed
See detailCyclin dependent kinase inhibitor (CDKN1B) gene variants in AIP mutation-negative familial isolated pituitary adenomas (FIPA) kindreds
Tichomirowa, M.; Lee, M.; Barlier, A. et al

in Endocrine-Related Cancer (2012), 19

Detailed reference viewed: 19 (6 ULg)
Full Text
Peer Reviewed
See detailAdrenal involvement in MEN1. Analysis of 715 cases from the Groupe d'etude des Tumeurs Endocrines database.
Gatta-Cherifi, B.; Chabre, O.; Murat, A. et al

in European Journal of Endocrinology (2012), 166(2), 269-279

Objective Limited data regarding adrenal involvement in multiple endocrine neoplasia type 1 (MEN1) is available. We describe the characteristics of MEN1-associated adrenal lesions in a large cohort to ... [more ▼]

Objective Limited data regarding adrenal involvement in multiple endocrine neoplasia type 1 (MEN1) is available. We describe the characteristics of MEN1-associated adrenal lesions in a large cohort to provide a rationale for their management. Methods Analysis of records from 715 MEN1 patients from a multicentre database between 1956 and 2008. Adrenal lesions were compared with those from a multicentre cohort of 144 patients with adrenal sporadic incidentalomas. Results Adrenal enlargement was reported in 20.4% (146/715) of patients. Adrenal tumours (>10 mm in size) accounted for 58.1% of these cases (10.1% of the whole patient cohort). Tumours were bilateral and >40 mm in size in 12.5 and 19.4% of cases respectively. Hormonal hypersecretion was restricted to patients with tumours and occurred in 15.3% of them. Compared with incidentalomas, MEN1-related tumours exhibited more cases of primary hyperaldosteronism, fewer pheochromocytomas and more adrenocortical carcinomas (ACCs; 13.8 vs 1.3%). Ten ACCs occurred in eight patients. Interestingly, ACCs occurred after several years of follow-up of small adrenal tumours in two of the eight affected patients. Nine of the ten ACCs were classified as stage I or II according to the European Network for the Study of Adrenal Tumors. No evident genotype/phenotype correlation was found for the occurrence of adrenal lesions, endocrine hypersecretion or ACC. Conclusions Adrenal pathology in MEN1 differs from that observed in sporadic incidentalomas. In the absence of relevant symptoms, endocrine biology can be restricted to patients with adrenal tumours and should focus on steroid secretion including the aldosterone-renin system. MEN1 is a high-risk condition for the occurrence of ACCs. It should be considered regardless of the size of the tumour. [less ▲]

Detailed reference viewed: 25 (0 ULg)
Full Text
See detailClinical characterization of cabergoline resistant prolactinomas : a multicenter experience on 92 patients
VROONEN, Laurent ULg; Jaffrain-Rea, M. L.; PETROSSIANS, Patrick ULg et al

in ENEA Munich - abstract book (2011, December)

Detailed reference viewed: 34 (4 ULg)
Full Text
Peer Reviewed
See detailGender-related differences in MEN1 lesion occurrence and diagnosis: a cohort study of 734 cases from the Groupe d''etude des Tumeurs Endocrines
goudet, p; Bonithon-Kopp, C.; Murat, A. et al

in European Journal of Endocrinology (2011)

Detailed reference viewed: 13 (1 ULg)
See detailFaut-il rechercher des anomalies génétiques constitutionnelles des gènes AIP et MEN1 chez un sujet jeune atteint d'adénome hypophysaire isolé sporadique ?
Cuny, T.; Pertuit, M.; Van bellinghen, J. F. et al

in Annales d'Endocrinologie - 28ème congrès de la société Française d'Endocrinologie (2011)

Detailed reference viewed: 23 (2 ULg)
Full Text
Peer Reviewed
See detailMutations AIP chez les jeunes patients en dessous de 30 ans avec adénome hypophysaire agressif
Beckers, Albert ULg; Tichomirowa, M.; Barlier, A. et al

in Annales d'Endocrinologie (2010, September), 71(5), 397

Detailed reference viewed: 29 (7 ULg)
Full Text
Peer Reviewed
See detailCaractéristiques des prolactinomes résistants aux agonistes dopaminergiques
Vroonen, Laurent ULg; Tamagno, G.; Naves, L. et al

in Annales d'Endocrinologie (2010, September), 71(5), 347

Detailed reference viewed: 46 (6 ULg)
Full Text
See detailMutations AIP chez les jeunes patients en-dessous de 30 ans avec adénome hypophysaire agressif
Beckers, Albert ULg; Tichomirowa, M.; Barlier, A. et al

in 27ème Congrès de la Société Française d'Endocrinologie - Deauville, 29 septembre - 2 octobre 2010 (2010, September)

Detailed reference viewed: 32 (4 ULg)
Full Text
Peer Reviewed
See detailRecherche de la mutation du gène CDKN1B dans les adénomes hypophysaires familiaux isolés (FIPA): analyse de 86 familles
Beckers, Albert ULg; Tichomirowa, M.; Pellegata, N. et al

in Annales d'Endocrinologie (2010, September), 71(5), 398

Detailed reference viewed: 24 (9 ULg)
See detailCyclin dependent kinase inhibitor 1B (CDKN1B) gene mutations in FIPA
Tichomirowa, M. A.; Pellegata, N. S.; Barlier, A. et al

in European Neuroendocrine Association - Liège, 22-25 septembre 2010 (2010, September)

Detailed reference viewed: 20 (3 ULg)
See detailHigh Prevalence of AIP Gene Mutations Following Focussed Screening in Young Patients with Sporadic Pituitary Macroadenomas
Tichomirowa, M. A.; Barlier, A.; Daly, Adrian ULg et al

in European Neuroendocrine Association - Liège, 22-25 septembre 2010 (2010, September)

Detailed reference viewed: 22 (3 ULg)
Full Text
See detailCaractéristiques cliniques et réponses thérapeutiques des patients avec adénome hypophysaire mutés pour AIP : étude internationale sur 96 cas
Beckers, Albert ULg; Daly, Adrian ULg; Petrossians, Patrick ULg et al

in 27ème Congrès de la Société Française d'Endocrinologie - Deauville, 29 septembre - 2 octobre 2010 (2010, September)

Detailed reference viewed: 24 (2 ULg)
See detailComprehensive study about the characteristics of 80 dopaminergic agonist resistants prolactinomas
Vroonen, Laurent ULg; Tamagno, G.; Naves, L. et al

in European Neuroendocrine Association - Liège, 22-25 septembre 2010 (2010, September)

Detailed reference viewed: 22 (5 ULg)
Full Text
See detailRecherche de la mutation du gène CDKN1B dans les adénomes hypophysaires familiaux isolés (FIPA) : analyse de 86 familles
Beckers, Albert ULg; Tichomirowa, M.; Pellegata, N. et al

in 27ème Congrès de la Société Française d'Endocrinologie - Deauville, 29 septembre - 2 octobre 2010 (2010, September)

Detailed reference viewed: 32 (10 ULg)